Premium
Metabolomic Analysis of HER2‐positive Breast Cancer Cells
Author(s) -
Bush Jason A.,
Sahni Malika K.,
Ravindran Resmi K.,
Khan Imran H.,
Krishnan Viswanathan V.
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.658.10
Subject(s) - breast cancer , medicine , metabolomics , cancer , cancer research , protein tyrosine phosphatase , endocrinology , biology , cell culture , cell , tyrosine , biochemistry , bioinformatics , genetics
Purpose HER2‐positive breast cancer accounts for more than 20% of the diagnosed cases and is characterized by aggressive growth, increased disease recurrence, and poor prognosis. While much of the signaling mechanism(s) have been elucidated, the impact of HER2 positivity on cellular metabolism is not well understood. We examined (1) gene expression profiles of mammalian breast cancer cell lines with increasing HER2 expression levels (MCF10A, MDA‐MB‐468, MDA‐MB‐453, HCC1954, HCC2218) and correlated changes to metabolic expression profiles and (2) the effect of serum starvation and pervanadate treatment on the metabolic profiles of these HER2‐expressing cell lines. Methods Our study used a combination of 1 H‐NMR and 2D‐NMR (TOCSY), multivariate analyses, and protein expression validation in human breast cancer cell lines (untreated, serum‐starved, serum‐starved with pervanadate treatment). Results We found that both gene and metabolic expression profiles of HER2‐positive cell lines correlated with leucine and isoleucine biosynthesis (p‐value < 0.05). Comparative analyses of profiles from untreated, serum‐starved, and serum‐starved with pervanadate‐treated cell samples revealed that lactate concentration (p‐value <0.05) dropped significantly with serum starvation and pervanadate treatment consistent with reduced glycolytic metabolism and potentially mediated through suppression of tyrosine phosphatase activity. Conclusion This study highlights important metabolites that are potential biomarkers of HER2‐positive breast cancer and suggests alternate/novel pathways to consider for future understanding and treatment. Support or Funding Information This work was funded in part through intramural programs at Fresno State to MKS and JAB, and through the NIGMS 1SC3GM122630‐01 to JAB. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .